ScreenerHero

CPIXCumberland Pharmaceuticals Inc.

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · cumberlandpharma.com
7.650USD0.00%Mkt Cap: 114.62M $P/E: —

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment o…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap114.62M $
Enterprise Value112.89M $
Revenue (TTM)44.30M $
Gross Profit37.85M $
Net Income (TTM)-2.84M $
Revenue/Share2.981 USD
Last Price7.650 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees88
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)53.57
PEG1.67
EV/EBITDA102.94
EV/Revenue2.55
P/S2.54
P/B6.44
EPS (TTM)-0.21
EPS (Forward)0.14
52W Range
1.85088% of range8.450
52W High8.450 USD
52W Low1.850 USD
Profitability
Gross Margin85.02%
Oper. Margin-1898.65%
EBITDA Margin2.48%
Profit Margin-6.37%
ROE-11.40%
ROA-3.69%
Growth
Revenue Growth-56.30%
Earnings Growth—
Cash Flow & Leverage
Operating CF4.93M $
CapEx (TTM)182.31K $
FCF Margin-0.43%
FCF Yield-0.17%
Net Debt851.78K $
Net Debt/EBITDA0.78
Balance Sheet
Debt/Equity0.41
Current Ratio0.96
Quick Ratio0.49
Book Value/Sh1.164 USD
Cash/Share0.2580 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateAug 3, 2026
Pay DateJul 31, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.14.98M
Float8.75M
Insiders41.60%
Institutions16.53%
Short Interest
Short Ratio3.3d
Short % Float4.41%
Short % Out.2.58%
Shares Short386.52K
Short (prev mo.)242.41K
Technical
SMA 506.808 (+12.4%)
SMA 2004.510 (+69.6%)
Beta0.11
S&P 52W Chg18.16%
Avg Vol (30d)125.66K
Avg Vol (10d)76.53K
Technical Indicators
RSI (14)56.6
MACD0.2964
MACD Signal0.3273
MACD Hist.-0.0309
BB Upper8.372 USD
BB Middle7.391 USD
BB Lower6.410 USD
BB Width26.55%
ATR (14)0.5934 USD
Vol Ratio (20d)0.28x